Trump's Generic Drug Tariff Plan Sparks Selling in Pharma Stocks
UPSC / SSC current affairs note · Economy
Why in news
The Nifty Pharma index fell 1.31% on Wednesday after U.S. President Donald Trump announced a phased tariff plan on imported generic medicines. This has raised concerns over the long-term earnings outlook for Indian pharmaceutical companies with significant exposure to the U.S. market.
Background
The U.S. is the largest overseas market for Indian pharmaceutical companies, with India exporting nearly USD 9.7 billion worth of pharmaceutical products annually. Generic medicines account for a substantial share of these exports.
Key facts
Trump announced imported generic medicines will continue to attract 0% tariff for the first two years.
After two years, tariffs will be phased: 100% in the third year and 200% from the fourth year onwards.
The proposal aims to encourage manufacturing of generic medicines within the U.S.
Nifty Pharma index declined 1.31% on the day of the announcement.
Sun Pharma, Lupin, and Cipla declined up to 4%; Dr. Reddy's, Aurobindo Pharma, Zydus Lifesciences, Glenmark, and Piramal Pharma also fell.
India exports nearly USD 9.7 billion worth of pharmaceutical products to the U.S. annually.
The two-year duty-free period provides time for Indian companies to evaluate strategic options like expanding U.S. manufacturing or diversifying markets.
Prelims pointers
- Nifty Pharma index
- U.S. President Donald Trump
- Generic medicines
- Tariff: 0% for 2 years, then 100% in year 3, 200% from year 4
- India's pharma exports to U.S.: ~USD 9.7 billion annually
Mains angles
- Impact of U.S. trade policy on Indian pharmaceutical exports
- Challenges and opportunities for Indian pharma in diversifying markets
- Strategic options for Indian pharma companies in response to tariff hikes